- Home
- CEP vs SGHT Comparison
CEP vs SGHT Comparison
Compare CEP & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- SGHT
- Stock Information
- Founded
- CEP 2020
- SGHT 2011
- Country
- CEP United States
- SGHT United States
- Employees
- CEP N/A
- SGHT N/A
- Industry
- CEP
- SGHT Medical Specialities
- Sector
- CEP
- SGHT Health Care
- Exchange
- CEP NYSE
- SGHT Nasdaq
- Market Cap
- CEP 516.2M
- SGHT 157.7M
- IPO Year
- CEP 2024
- SGHT 2021
- Fundamental
- Price
- CEP $42.13
- SGHT $3.91
- Analyst Decision
- CEP
- SGHT Buy
- Analyst Count
- CEP 0
- SGHT 7
- Target Price
- CEP N/A
- SGHT $4.02
- AVG Volume (30 Days)
- CEP 3.4M
- SGHT 182.9K
- Earning Date
- CEP 01-01-0001
- SGHT 05-08-2025
- Dividend Yield
- CEP N/A
- SGHT N/A
- EPS Growth
- CEP N/A
- SGHT N/A
- EPS
- CEP 0.25
- SGHT N/A
- Revenue
- CEP N/A
- SGHT $78,109,000.00
- Revenue This Year
- CEP N/A
- SGHT N/A
- Revenue Next Year
- CEP N/A
- SGHT $11.68
- P/E Ratio
- CEP $159.75
- SGHT N/A
- Revenue Growth
- CEP N/A
- SGHT N/A
- 52 Week Low
- CEP $9.99
- SGHT $2.03
- 52 Week High
- CEP $59.75
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- SGHT 63.75
- Support Level
- CEP N/A
- SGHT $3.36
- Resistance Level
- CEP N/A
- SGHT $3.75
- Average True Range (ATR)
- CEP 0.00
- SGHT 0.26
- MACD
- CEP 0.00
- SGHT 0.02
- Stochastic Oscillator
- CEP 0.00
- SGHT 85.37
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.